Skip to main content
Premium Trial:

Request an Annual Quote

Integrated DNA Technologies and Aldevron's GMP SpyFi Cas9 Nuclease

Aldevron and Integrated DNA Technologies have released GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, which is the trade name for Aldevron's research grade and GMP products, was developed through a partnership between the two companies. The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity, Aldevron said. Its release provides researchers and scientists with a consistent product for gene editing programs, from discovery through clinical and commercial manufacturing. 

This specific Cas9 protein variant resulted from a substantial amount of development of the wild-type Streptococcus pyogenes Cas9 sequence. This nuclease also functions well in ribonucleoprotein (RNP) delivery format and is compatible with ex vivo gene editing protocols. GMP-grade SpyFi Cas9 Nuclease is available in 1 mg and 10 mg vials.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more